The Columbus Community Clinical Oncology Program has been an extremely successful CCOP. In the eight years since our formation, our focus on the achievement of certain specific aims has allowed us to expand.
Those aims are: to decrease morbidity and mortality from malignant disease through active participation in cancer control and treatment research; to increase the involvement of primary care physicians; to extend and refine our administrative and organizational structure to facilitate the recruitment of patients to protocols; to develop cost effective, efficient methods of data management; to continue to extend the benefits of advances in cancer care to the populations of Central Ohio; to maximize the dissemination of advances in oncology to primary care and subspeciality physicians; to maintain our current, effective system of internal quality control; and to participate in efforts of the NCI to evaluate the impact of treatment and cancer control research in meeting Year 2000 Goals. As one of the first Community Clinical Oncology Program's, Columbus CCOP has spent the past eight years acquiring unique resources that distinguish it from other CCOPs. Columbus CCOP's Principal Investigator and Co-Investigators have substantial personal track records and an evident long term commitment to clinical research. For more than a decade, the Columbus CCOP has maintained high levels of accrual to NCI clinical trials and has had significant accrual to cancer control protocols. Our expertise and accuracy in data management has allowed us to become consultants to other CCOPs, and our quality control ratings from SWOG are always at the top of all CCOP institutions. The network of community hospitals involved in our CCOP form a strong base for cancer control research activities, and each institution has made a major financial commitment to the CCOP, at $70,000 per institution per year. The Columbus CCOP has a distinguished group of key personnel, who have contributed to both the scientific and organizational aspects of our CCOP. The impressive history of our CCOP, combined with the significant resources we have demonstrated in this application, guarantees the NCI of a superior community collaborator.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA035261-07
Application #
3557640
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1983-09-30
Project End
1995-05-31
Budget Start
1990-08-01
Budget End
1991-05-31
Support Year
7
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Columbus Community Clinical Oncology Prg
Department
Type
DUNS #
City
Columbus
State
OH
Country
United States
Zip Code
43215
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Deininger, Michael W; Kopecky, Kenneth J; Radich, Jerald P et al. (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223-32

Showing the most recent 10 out of 151 publications